Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(7):1813–1821. doi: 10.1111/j.1476-5381.1996.tb15608.x

Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity.

G Coruzzi 1, M Adami 1, C Pozzoli 1, F Giorgi 1, G Bertaccini 1
PMCID: PMC1909814  PMID: 8842448

Abstract

1. A series of histamine H2 receptor antagonists with different lipophilicity were tested in cardiac and gastric assays in order to reveal possible differences in receptor affinity. Lipophilicity of the compounds was expressed as CLOG P (theoretically-determined logarithm of octanol:water partition coefficient) and log k' (logarithm of capacity factor, experimentally-determined by reverse-phase high performance liquid chromatography). 2. Aminopotentidine (APT) and iodoaminopotentidine (I-APT), which are both lipophilic compounds, behaved as insurmountable antagonists of histamine responses in rat isolated gastric fundus (pKB = 6.20 +/- 0.16 and 6.89 +/- 0.19, respectively) and guinea-pig isolated papillary muscle (pKB = 6.34 +/- 0.37 and 6.81 +/- 0.26, respectively). They were approximately as effective as ranitidine (RAN) in reducing histamine-induced acid secretion in the anaesthetized rat, ID50 values being 0.018 +/- 0.02, 0.020 +/- 0.03 and 0.036 +/- 0.01 mumol kg-1 i.v. for APT, I-APT and RAN, respectively. Both APT and I-APT had a significantly longer duration of action than RAN. 3. The hydrophilic compound, SK&F 92857, was inactive up to 10 microM in modifying histamine-induced acid secretion in the isolated rat stomach. In the papillary muscle, low concentrations (0.1-1 microM) of this compound produced a competitive antagonism of the histamine responses (pA2 value = 7.38 +/- 0.11), while a higher concentration (10 microM) significantly reduced the maximal response to histamine. 4. RAN competitively antagonized histamine effects with a comparable affinity in cardiac and gastric preparations (pA2 values were 6.42 +/- 0.09 and 6.78 +/- 0.38 in heart and stomach, respectively). 5. Results obtained in this study clearly showed that the discrepancies between gastric and cardiac effects observed for some H2 antagonists are not explained solely by differences in lipophilicity of compounds. Moreover, the significant correlation found between CLOG P and log k' parameter, which takes into account, besides their lipophilicity, the ionization of the molecules, suggests that ionization has a similar influence for all the molecules on the partition between the lipophilic and aqueous phase.

Full text

PDF
1813

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Angus J. A., Black J. W. Analysis of anomalous pKb values for metiamide and atropine in the isolated stomach of the mouse. Br J Pharmacol. 1979 Sep;67(1):59–65. [PMC free article] [PubMed] [Google Scholar]
  3. Bertaccini G., Coruzzi G. Effect of impromidine (SK&F 92676) on the isolated papillary muscle of the guinea-pig. Br J Pharmacol. 1981 Feb;72(2):197–199. doi: 10.1111/j.1476-5381.1981.tb09113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Black J. W., Leff P., Shankley N. P. Further analysis of anomalous pKB values for histamine H2-receptor antagonists on the mouse isolated stomach assay. Br J Pharmacol. 1985 Nov;86(3):581–587. doi: 10.1111/j.1476-5381.1985.tb08934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buschauer A., Mohr R., Schunack W. Synthesis and histamine H2-receptor antagonist activity of 4-(1-pyrazolyl)butanamides, guanidinopyrazoles, and related compounds. Arch Pharm (Weinheim) 1995 Apr;328(4):349–358. doi: 10.1002/ardp.19953280411. [DOI] [PubMed] [Google Scholar]
  6. Buschauer A. Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J Med Chem. 1989 Aug;32(8):1963–1970. doi: 10.1021/jm00128a045. [DOI] [PubMed] [Google Scholar]
  7. Calcutt C. R., Ganellin C. R., Griffiths R., Leigh B. K., Maguire J. P., Mitchell R. C., Mylek M. E., Parsons M. E., Smith I. R., Young R. C. Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist. Br J Pharmacol. 1988 Jan;93(1):69–78. doi: 10.1111/j.1476-5381.1988.tb11406.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coruzzi G., Adami M., Bertaccini G. Action of histamine and of some H2-antagonists on gastric secretion 'in vitro'. Agents Actions. 1984 Apr;14(3-4):516–521. doi: 10.1007/BF01973862. [DOI] [PubMed] [Google Scholar]
  9. Coruzzi G., Adami M., Pozzoli C., Buschauer A., Bertaccini G. Different activities of impromidine and related phenyl-(pyridylalkyl)guanidines at cardiac and gastric H2 receptors. Inflamm Res. 1995 Apr;44 (Suppl 1):S108–S109. doi: 10.1007/BF01674420. [DOI] [PubMed] [Google Scholar]
  10. Coruzzi G., Adami M., Pozzoli C., Poli E., Bertaccini G. Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2-receptors. Pharmacology. 1994 Feb;48(2):69–76. doi: 10.1159/000139164. [DOI] [PubMed] [Google Scholar]
  11. Deutsch S. I., Rosse R. B., Kendrick K. A., Fay-McCarthy M., Collins J. P., Jr, Wyatt R. J. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol. 1993 Dec;16(6):518–524. [PubMed] [Google Scholar]
  12. Kaumann A. J., Frenken M. A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Jan;328(3):295–300. doi: 10.1007/BF00515556. [DOI] [PubMed] [Google Scholar]
  13. Kramer K., Bast A., Timmerman H. Relation between pharmacological response and receptor binding with histamine blocking drugs. Irreversible antagonism of three analogues of mifentidine on right atrium and cerebral cortex of the guinea-pig. Agents Actions. 1987 Jun;21(1-2):41–48. doi: 10.1007/BF01974919. [DOI] [PubMed] [Google Scholar]
  14. Robertson M. J., Barnes J. C., Drew G. M., Clark K. L., Marshall F. H., Michel A., Middlemiss D., Ross B. C., Scopes D., Dowle M. D. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol. 1992 Dec;107(4):1173–1180. doi: 10.1111/j.1476-5381.1992.tb13425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Robertson M. J., Dougall I. G., Harper D., McKechnie K. C., Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci. 1994 Oct;15(10):364–369. doi: 10.1016/0165-6147(94)90156-2. [DOI] [PubMed] [Google Scholar]
  16. Ruat M., Traiffort E., Bouthenet M. L., Schwartz J. C., Hirschfeld J., Buschauer A., Schunack W. Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H2 receptor using [125I]iodinated probes. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1658–1662. doi: 10.1073/pnas.87.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shankley N. P., Black J. W., Ganellin C. R., Mitchell R. C. Correlation between log POCT/H2O and pKB estimates for a series of muscarinic and histamine H2-receptor antagonists. Br J Pharmacol. 1988 May;94(1):264–274. doi: 10.1111/j.1476-5381.1988.tb11523.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Traiffort E., Pollard H., Moreau J., Ruat M., Schwartz J. C., Martinez-Mir M. I., Palacios J. M. Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine. J Neurochem. 1992 Jul;59(1):290–299. doi: 10.1111/j.1471-4159.1992.tb08903.x. [DOI] [PubMed] [Google Scholar]
  19. Young R. C., Mitchell R. C., Brown T. H., Ganellin C. R., Griffiths R., Jones M., Rana K. K., Saunders D., Smith I. R., Sore N. E. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem. 1988 Mar;31(3):656–671. doi: 10.1021/jm00398a028. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES